F10 and cancer: All anticoagulation strategies (factor Xa inhibition, vitamin K antagonist, and antithrombin activation) have limited efficacy and cannot prevent the occurrence of cancer-associated vascular occlusion (33–36), which often recurs despite treatment (37–41).